Integrated Advisors Network LLC Purchases 67,199 Shares of Merck & Co., Inc. (NYSE:MRK)

Integrated Advisors Network LLC raised its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 299.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 89,628 shares of the company’s stock after buying an additional 67,199 shares during the quarter. Integrated Advisors Network LLC’s holdings in Merck & Co., Inc. were worth $8,171,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. TFO TDC LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at approximately $31,000. Moisand Fitzgerald Tamayo LLC lifted its stake in Merck & Co., Inc. by 69.9% in the 2nd quarter. Moisand Fitzgerald Tamayo LLC now owns 367 shares of the company’s stock valued at $33,000 after acquiring an additional 151 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at approximately $47,000. GW&K Investment Management LLC lifted its stake in Merck & Co., Inc. by 85.8% in the 1st quarter. GW&K Investment Management LLC now owns 561 shares of the company’s stock valued at $46,000 after acquiring an additional 259 shares in the last quarter. Finally, Steward Financial Group LLC raised its stake in shares of Merck & Co., Inc. by 26.7% during the 2nd quarter. Steward Financial Group LLC now owns 727 shares of the company’s stock worth $66,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 73.33% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK traded down $0.08 during trading hours on Thursday, hitting $106.82. 5,750,005 shares of the company were exchanged, compared to its average volume of 9,894,878. The company has a market cap of $270.83 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 1.42 and a beta of 0.38. Merck & Co., Inc. has a fifty-two week low of $71.50 and a fifty-two week high of $107.30. The company has a quick ratio of 1.22, a current ratio of 1.46 and a debt-to-equity ratio of 0.64. The firm’s fifty day moving average is $94.50 and its 200 day moving average is $91.59.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its earnings results on Thursday, October 27th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.18. The company had revenue of $14.96 billion for the quarter, compared to analyst estimates of $14.05 billion. Merck & Co., Inc. had a return on equity of 46.57% and a net margin of 25.88%. Merck & Co., Inc.’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.75 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 7.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRK has been the topic of a number of research analyst reports. Cantor Fitzgerald increased their price target on Merck & Co., Inc. from $107.00 to $120.00 in a research note on Friday, October 28th. Wells Fargo & Company increased their price target on Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Friday, October 28th. Atlantic Securities increased their price target on Merck & Co., Inc. from $116.00 to $122.00 and gave the company an “overweight” rating in a research note on Friday, October 28th. Citigroup increased their price target on Merck & Co., Inc. to $105.00 in a research note on Tuesday, November 15th. Finally, StockNews.com initiated coverage on Merck & Co., Inc. in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $106.00.

Insider Activity at Merck & Co., Inc.

In related news, insider Kenneth C. Frazier sold 300,000 shares of the firm’s stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $100.75, for a total value of $30,225,000.00. Following the sale, the insider now directly owns 706,283 shares of the company’s stock, valued at $71,158,012.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Kenneth C. Frazier sold 300,000 shares of the firm’s stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $100.75, for a total value of $30,225,000.00. Following the sale, the insider now directly owns 706,283 shares of the company’s stock, valued at $71,158,012.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert M. Davis sold 167,613 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $102.44, for a total value of $17,170,275.72. Following the completion of the sale, the chief executive officer now directly owns 247,593 shares in the company, valued at $25,363,426.92. The disclosure for this sale can be found here. Insiders have sold 1,081,815 shares of company stock valued at $108,575,433 over the last ninety days. 0.29% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.